Combination treatment for depression and anxiety
AssigneePfizer Inc.
InventorsSusan B. Sobolov-Jaynes, John A. Lowe III, Stafford McLean
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an NK-3 antagonist agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist.
Claims35
A pharmaceutical composition for the treatment of anxiety or depression in a mammal, comprising:
- (a) an NK-3 antagonist or a pharmaceutically acceptable salt thereof;
- (b) a CNS-penetrant NK-1 receptor antagonist or pharmaceutically acceptable salt thereof;
- and (c) a pharmaceutically acceptable carrier;
- wherein the active agents “a” and “b” above are present in amounts that render the composition effective in treating, respectively, anxiety or depression.
A method of treating anxiety or depression in a mammal, comprising administering to said mammal:
- (a) an NK-3 antagonist or a pharmaceutically acceptable salt thereof;
- and (b) a CNS-penetrant NK-1 receptor antagonist or pharmaceutically acceptable salt thereof;
- wherein the active agents “a” and “b” above are present in amounts that render the combination of the two agents effective in treating, respectively, anxiety or depression.
Dependencies are inferred from the claim text.